Hyaluronic Acid Bone Morphogenetic Protein Joint Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis (OA) lack effective methods to slow or reverse the disease progression, with existing therapies providing limited pain relief and potential side effects, and there is a need for improved compositions and methods to address joint pain and structural degeneration.
Innovation Solution
A method involving a combination of hyaluronic acid (HA) and bone morphogenetic protein (BMP), where BMP is precipitated and dispersed in the HA solution at a specific pH range, allowing it to become solubilized and biologically active upon injection, enhancing joint treatment by promoting bone and cartilage regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If BMP is combined with HA solution at neutral pH, then the mixture is stable and easy to store, but BMP precipitates and loses biological activity
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the HA solution to an acidic range (pH 2-4) before combining with BMP. This pH modification prevents BMP precipitation and maintains its biological activity, while the acidic HA solution remains stable. The key parameter change is the pH level, which resolves the contradiction between mixture stability and BMP activity preservation.
Solution Approach 2:
The patent uses an intermediary approach by employing a specific pH buffer system or acidified HA solution as a mediator between BMP and the joint environment. This intermediary acidic environment allows BMP to remain soluble and active during storage and administration, while still enabling its biological function in the joint after injection.
2Reliability
If BMP is kept soluble and biologically active, then treatment effectiveness is improved, but the formulation becomes unstable and difficult to store
Solution Approach 1:
The patent resolves this contradiction by changing the pH parameter of the HA solution to acidic levels (pH 2-4). This parameter change enables BMP to remain soluble and biologically active in the formulation while maintaining stability during storage. The acidic environment prevents premature precipitation and preserves both solubility and stability.
3Duration of action of moving object
If HA concentration is increased to improve joint lubrication, then pain relief duration increases, but the volume of injection increases
Solution Approach 1:
The patent applies merging by combining HA with BMP in a single injectable formulation. This combination allows the therapeutic effects of both molecules to be achieved simultaneously in a unified treatment, potentially reducing the need for separate injections and optimizing the balance between pain relief duration and injection volume.
Solution Approach 2:
The patent uses composite materials by creating a composite injectable formulation containing both HA and BMP molecules. This composite approach enables synergistic effects where HA provides lubrication and cushioning while BMP promotes tissue regeneration, achieving enhanced therapeutic outcomes within acceptable volume constraints.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HA-BMP combination provides sustained pain relief and potential structural benefits by promoting chondrogenesis, with the BMP regaining biological activity post-injection, offering an improved treatment for OA beyond existing therapies.
Implementation Method 1
combining a solution of hyaluronic acid (HA) with a bone morphogenetic protein (BMP) to form a mixture in which the BMP is precipitated and dispersed in the solution of HA
Data Source
AI summary
Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.